QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=DB04DB8A4B8F7B023C54339276056B5C;jsessionid=B893C37E4F5CBF33871D94983F4C0708;jsessionid=A921EFA6BB93C353C5B1A9C52DC35C39;jsessionid=29F23DFEC4AA80A60EED7ECA108DB4A0;jsessionid=A789F13275042BC25CF30384C84C08A0;jsessionid=C596D9E817238F347F778384FBA782A7 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=DB04DB8A4B8F7B023C54339276056B5C;jsessionid=B893C37E4F5CBF33871D94983F4C0708;jsessionid=A921EFA6BB93C353C5B1A9C52DC35C39;jsessionid=29F23DFEC4AA80A60EED7ECA108DB4A0;jsessionid=A789F13275042BC25CF30384C84C08A0;jsessionid=C596D9E817238F347F778384FBA782A7